Genomic and Clinical Landscape of Metastatic HR+ Breast Cancers With ESR1 Alterations
Read it now on PracticeUpdate.com
Related Articles
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma
The analysis of tumor DNA by whole-genome sequencing (WGS) is increasingly utilized for the identification of clinically relevant DNA aberrations. We aim to assess whether…
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
Squamous cell carcinoma (SCC) of unknown primary (SCCUP) refers to any SCC for which the primary tumor origin cannot be identified despite guideline-directed evaluation. Although…
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Fibroblast growth factor receptor 2b (FGFR2b) is a novel protein biomarker expressed in gastric and gastroesophageal junction tumors (GC/GEJC). Phase III trials are evaluating the…
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
The European Society for Medical Oncology (ESMO) Clinical Practice Guideline for the diagnosis, treatment and follow-up of patients with newly diagnosed and relapsed epithelial ovarian…
Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers
Biliary tract cancer (BTC) remains a highly aggressive malignancy with limited treatment options and poor prognosis. To explore the association between KRAS variants and survival/therapeutic…
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy
Anal squamous-cell carcinoma (ASCC) is a rare cancer. Immune checkpoint inhibitors (ICIs) are used as a second-line treatment. We aimed to analyze the genomic and…
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer
The purpose of this study was to assess the efficacy and safety of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine/nab-paclitaxel (GnP) in previously…
Financial toxicity and socioeconomic impact of cancer in Europe
Even with universal health care, patients living with cancer often face substantial treatment-related costs and income loss in Europe. Insights into the socioeconomic impact of…
Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings
The REMORA trial demonstrated efficacy and safety of lenvatinib in patients previously treated for advanced thymic carcinoma. However, more data regarding its use in clinical…
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma☆
Sacituzumab govitecan (SG) is an antibody–drug conjugate associated with clinically meaningful responses as advanced-line treatment of metastatic urothelial carcinoma (mUC). Practically, SG has been most…